ArticleCancer medicine2026
SGO1 and SGO2 are Associated With Disease Progression and an Immunosuppressive Microenvironment in Papillary Renal Cell Carcinoma.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundShugoshin proteins SGO1 and SGO2 regulate chromosome cohesion and segregation during mitosis and meiosis, and their aberrant expression is implicated in several cancers. However, the mechanistic involvement of these two proteins in papillary renal cell carcinoma (KIRP) and their contribution to immune evasion remains unclear. Therefore, in the present study, we aimed to determine SGO1 and SGO2 expression patterns and prognostic significance, clarify their functional involvement in driving tumor progression, and evaluate their impact on the tumor immune microenvironment.
methodsWe performed an integrative analysis using multi-omics datasets retrieved from TCGA, GTEx, and GEO, complemented by single-cell transcriptomics, immunohistochemistry of patient samples, and functional assays in renal cancer cell lines. We also investigated the expression, clinical relevance, and mechanistic roles of SGO1 and SGO2 in KIRP progression and tumor immune regulation.
resultsSGO1 and SGO2 were significantly upregulated in KIRP, correlating with advanced tumor stage and poor overall survival. Receiver operating characteristic analyses demonstrated strong diagnostic performance, particularly when SGO1 and SGO2 were evaluated jointly. Functional knockdown experiments revealed that both SGO1 and SGO2 promote the proliferation, migration, and invasion of renal cancer cells. Gene enrichment analyses further linked these proteins to E2F signaling, genomic stability, and immune-related pathways. Importantly, high SGO1 and SGO2 expression was strongly associated with increased infiltration of immunosuppressive cells, including regulatory T cells, M2 macrophages, cancer-associated fibroblasts, and myeloid-derived suppressor cells, suggesting their potential contribution to an immune-evasive tumor microenvironment.
conclusionsSGO1 and SGO2 are associated with aggressive tumor biology in papillary renal cell carcinoma and correlate with remodeling of the tumor immune microenvironment toward an immunosuppressive state. Importantly, while these findings highlight a strong association with the tumor immune microenvironment, they remain correlative, and further mechanistic studies are warranted to establish a direct causal relationship. Nevertheless, their associations with both tumor progression and immunosuppressive features suggest potential as prognostic biomarkers and targets for future mechanistic studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.